Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of omecamtiv mecarbil in healthy volunteers of Japanese and non-Japanese ethnicity

Next Previous
Trial Profile

Phase I trial of omecamtiv mecarbil in healthy volunteers of Japanese and non-Japanese ethnicity

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary) ; Omecamtiv mecarbil (Primary)
  • Indications Acute heart failure; Chronic heart failure; Heart failure
  • Focus Pharmacokinetics
  • Sponsors Amgen

    • Most Recent Events

    • 20 Aug 2021 Results of two clinical studies evaluating pharmacokinetics, tolerability, and safety of single and multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian subjects published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 27 Oct 2014 Top-line results published in a Cytokinetics media release.
    • 27 Oct 2014 Status changed from recruiting to completed, as reported by a Cytokinetics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top